Patent 10952962 was granted and assigned to Quva Pharma, Inc on March, 2021 by the United States Patent and Trademark Office.
Disclosed herein is a ready-to-use liquid formulation comprising lidocaine hydrochloride and epinephrine hydrochloride. Also disclosed herein is a process for preparing a ready-to-use liquid formulation comprising lidocaine hydrochloride and epinephrine hydrochloride, as well as methods for using the ready-to-use liquid formulation.